Global Cervical Cancer Diagnostic Tests Market 2023by Deepak Kumar Sr. SEO Executive
Cervical cancer diagnostic tests are used widely for detection of the precancerous or cancerous lesions in the cervix of a female. The cervical cancer diagnostics is the initial screening of the patients, done through Pap smear and HPV testing, in the next stage colposcopy and biopsy are used to further confirm the furthers. After the diagnosis performed successfully the patients then goes through imaging tests to start the grade of cancer.
Read market report here : http://bit.ly/2p0QrmR
Based on various types of diagnostic test the global cervical cancer diagnostics market can be broadly classified as, Pap Smear Tests, Colposcopy Tests and ECC Procedures. Based on the various age groups of the patients the global cervical cancer diagnostics market can be broadly classified as 20-40 years and above 40 years.
Over-diagnosis and over-treatment are some of the major hindrance to the growth of cervical cancer diagnostic market. Also the Pap screening test has very high false positive results and low sensitivity rate in the cervical cancer detection in recent years.
Get sample report here : http://bit.ly/2G9Hccp
North America was the largest market for cervical cancer diagnostic test in 2014. The market dominance of North America is attributed to the high awareness of women towards the disease prevention in this region. Asia Pacific is the fasted growing market of cervical cancer diagnostic test attributed to the growing prevalence of the cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea and Australia.
Some of the major players operating in global cervical cancer diagnostics test market include, Abbott Laboratories, Hologic, Inc., Becton, Roche Diagnostics, Dickinson and Company, OncoHealth Corporation, Qiagen N.V., Guided Therapeutics, Inc., Quest Diagnostics, Femasys, Inc., and Zilico Ltd.
Created on Mar 9th 2018 05:04. Viewed 1,090 times.
No comment, be the first to comment.